Sotorasib + Panitumumab Beneficial for Chemorefractory Metastatic CRC
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, Oct. 24, 2023 -- For patients with chemorefractory metastatic colorectal cancer, the KRAS G12C inhibitor sotorasib in combination with the epidermal growth factor receptor inhibitor panitumumab results in longer progression-free survival than standard treatment, according to a study published online Oct. 22 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the European Society for Medical Oncology, held from Oct. 20 to 24 in Madrid.
Marwan G. Fakih, M.D., from the City of Hope Comprehensive Cancer Center in Duarte, California, and colleagues randomly assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib 960 mg once daily plus panitumumab, sotorasib 240 mg once daily plus panitumumab, or the investigator's choice of trifluridine-tipiracil or regorafenib (standard care; 53, 53, and 54 patients, respectively).
The researchers found that the median progression-free survival was 5.6 and 3.9 months versus 2.2 months in the 960-mg and 240-mg sotorasib-panitumumab groups, respectively, versus the standard-care group after a median follow-up of 7.8 months. The hazard ratio for disease progression or death was 0.49 and 0.58 in the 960-mg and 240-mg sotorasib-panitumumab groups, respectively, compared with the standard-care group. In the 960-mg and 240-mg sotorasib-panitumumab groups and the standard-care group, the objective response rate was 26.4, 5.7, and 0 percent, respectively. Overall, treatment-related adverse events of grade 3 or higher occurred in 35.8, 30.2, and 43.1 percent, respectively.
"These findings are important in the context of the poor survival outcomes associated with KRAS G12C mutation in patients with colorectal cancer," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Amgen, which manufactures sotorasib and panitumumab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Neoadjuvant Nivolumab, Ipilimumab Safe for dMMR Colon Cancer
WEDNESDAY, June 5, 2024 -- Neoadjuvant nivolumab plus ipilimumab has an acceptable safety profile in patients with locally advanced mismatch repair-deficient (dMMR) colon cancer...
Lowering FIT Positivity Thresholds Improves Sensitivity, Specificity
WEDNESDAY, June 5, 2024 -- Lowering the fecal immunochemical test (FIT) positive threshold yields levels of sensitivity and specificity that are comparable to those reported for...
Digestive Disease Week, May 18-21
Digestive Disease Week, the annual meeting sponsored by the American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society for...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.